RRM2 and pancreatic neoplasm: Correspondingly, in the cohort study by Itoi et al. [28], high transcript expression of RRM2 in 31 fine-needle aspiration biopsy specimens of advanced stage pancreatic cancer significantly correlated with a poor patient survival and resistance to gemcitabine.